期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/jpm12091430
关键词
multiple sclerosis; biomarkers; prognosis; clinically isolated syndrome; body fluid
资金
- MultipleMS project (Horizon 2020 European) [733161]
This study conducted a scoping review on prognostic biomarkers in MS, identifying a few biomarkers that can predict the risk of conversion from CIS to clinically definite MS, while others require further research to determine their reliability. Serum and CSF levels of neurofilaments are considered promising biomarkers for MS prognosis.
Multiple sclerosis (MS) is a complex demyelinating disease of the central nervous system, presenting with different clinical forms, including clinically isolated syndrome (CIS), which is a first clinical episode suggestive of demyelination. Several molecules have been proposed as prognostic biomarkers in MS. We aimed to perform a scoping review of the potential use of prognostic biomarkers in MS clinical practice. We searched MEDLINE up to 25 November 2021 for review articles assessing body fluid biomarkers for prognostic purposes, including any type of biomarkers, cell types and tissues. Original articles were obtained to confirm and detail the data reported by the review authors. We evaluated the reliability of the biomarkers based on the sample size used by various studies. Fifty-two review articles were included. We identified 110 molecules proposed as prognostic biomarkers. Only six studies had an adequate sample size to explore the risk of conversion from CIS to MS. These confirm the role of oligoclonal bands, immunoglobulin free light chain and chitinase CHI3L1 in CSF and of serum vitamin D in the prediction of conversion from CIS to clinically definite MS. Other prognostic markers are not yet explored in adequately powered samples. Serum and CSF levels of neurofilaments represent a promising biomarker.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据